Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Sarcoma: early-phase trial registry
58 of 129 indexed Sarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #92 of 28,707 conditions by registered trial count.
129 US clinical trials · 58 currently recruiting · #92 of 28,707 conditions by registered trial count
Sarcoma: 129 US clinical trials tracked, 58 recruiting.
Sarcoma is the subject of 129 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 80 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 26 of these trials.
Enrollment posture brief
Registry condition sarcoma
OPEN 58 | RECR 45% | LATE 10 | EARLY 80 | RANK #92 | SPON 26
Volume-matched condition peers
Nearest open-share peer: Cancer (45% recruiting · 621 trials)
Sarcoma lists 58 open slots (45% of 129 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Sarcoma is recruiting above its size-band peers.
58 of 129 indexed trials (45%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Sarcoma research.
Memorial Sloan Kettering Cancer Center accounts for 26 of 129 trials (20.2%). 72 distinct sponsors appear on at least one study for this condition label.
-
Most Sarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 123 trials that report a genuine target (sentinel values excluded). 80 of those (65%) plan for fewer than 100 participants.
-
Sarcoma research is mostly interventional.
106 interventional and 23 observational studies make up this index (82.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
129 total, page 2 of 3
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT07447050
A Checklist (Advanced Care Planning) for The Assessment of Mobility Needs in Patients With Sarcoma
Fred Hutchinson Cancer Center
NCT05835154
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
University of Colorado, Denver
NCT07125183
GRID Therapy for Extremity Soft Tissue Sarcoma
UNC Lineberger Comprehensive Cancer Center
NCT06073067
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
Duke University
NCT03144206
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Gabriel Tino
NCT06528769
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Washington University School of Medicine
NCT06904365
Palbociclib and Pembrolizumab in Sarcoma
John Rieth
NCT06113809
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group
Children's Oncology Group
NCT01117168
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
Memorial Sloan Kettering Cancer Center
NCT00582647
Genomic Structural Variation in Cancer Susceptibility
Memorial Sloan Kettering Cancer Center
NCT00996710
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics
NCT05812027
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics
NCT03678883
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT01223248
Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
CivaTech Oncology
NCT04033081
Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma
M.D. Anderson Cancer Center
NCT05216029
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
NCT03282344
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
NCT01590069
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
NCT00077285
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT02713269
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
NCT03069378
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Baylor College of Medicine
NCT00902044
Study of Abemaciclib in Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT02846987
SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma
Sarcoma Oncology Research Center
NCT03778996
A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
NCT03414229
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
University of Iowa
NCT04634227
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03628209
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
Jonsson Comprehensive Cancer Center
NCT04457258
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
NCT05886634
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Memorial Sloan Kettering Cancer Center
NCT01189643
Bevacizumab/Doxorubicin/Radiation for Sarcoma
Massachusetts General Hospital
NCT01746238
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
University of Rochester
NCT03463408
Proton Pencil Beam Scanning GRID for Treatment of Bulky Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05121545
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
Memorial Sloan Kettering Cancer Center
NCT02307630
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
Children's Oncology Group
NCT00006734
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Children's Oncology Group
NCT00354835
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
Alliance for Clinical Trials in Oncology
NCT00091351
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
NCT00369564
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus
Gynecologic Oncology Group
NCT00002546
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center
NCT00782145
Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds
Medical University of South Carolina
NCT02638298
Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
MabVax Therapeutics
NCT01141491
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
National Cancer Institute (NCI)
NCT00001209
iCAT for Recurrent/Refractory/HR Solid Tumors
Dana-Farber Cancer Institute
NCT01853345
Troglitazone in Treating Patients With Liposarcoma
Dana-Farber Cancer Institute
NCT00003058
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
NCT00004066
S0423 Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
SWOG Cancer Research Network
NCT00107419
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT00918281
Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors
Memorial Sloan Kettering Cancer Center
NCT00598741
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 37 |
| Phase 2 | 43 |
| Phase 3 | 8 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Sarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Sarcoma page
129 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Sarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Sarcoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcoma condition card totals 129 registered trials; most-linked intervention filgrastim; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.